XML 44 R28.htm IDEA: XBRL DOCUMENT
v3.23.1

Segment Information (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2023
Segment Reporting [Abstract] |
Disaggregation of Revenue [Table Text Block] |
| Three Months Ended March 31,
(in millions) | 2023 |  | 2022
Pharmaceutical Distribution and Specialty Solutions (1) (2) | $ | 46,497 |  |  | $ | 40,723 |
Nuclear and Precision Health Solutions (3) | 312 |  |  | 234 |
Pharmaceutical segment revenue | 46,809 |  |  | 40,957 |
Medical distribution and products (4) | 3,034 |  |  | 3,283 |
Cardinal Health at-Home Solutions | 650 |  |  | 601 |
Medical segment revenue | 3,684 |  |  | 3,884 |
Total segment revenue | 50,493 |  |  | 44,841 |
Corporate (5) | (6) |  |  | (5) |
Total revenue | $ | 50,487 |  |  | $ | 44,836 |
| Nine Months Ended March 31,
(in millions) | 2023 |  | 2022
Pharmaceutical Distribution and Specialty Solutions (1) (2) | $ | 139,435 |  |  | $ | 121,501 |
Nuclear and Precision Health Solutions (3) | 875 |  |  | 653 |
Pharmaceutical segment revenue | 140,310 |  |  | 122,154 |
Medical distribution and products (4) | 9,273 |  |  | 10,296 |
Cardinal Health at-Home Solutions | 1,986 |  |  | 1,822 |
Medical segment revenue | 11,259 |  |  | 12,118 |
Total segment revenue | 151,569 |  |  | 134,272 |
Corporate (5) | (10) |  |  | (11) |
Total revenue | $ | 151,559 |  |  | $ | 134,261 |
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services." (2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (3)Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts. (4)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division. (5)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block] | The following tables present revenue by geographic area:
| Three Months Ended March 31,
(in millions) | 2023 |  | 2022
United States | $ | 49,326 |  |  | $ | 43,710 |
International | 1,167 |  |  | 1,131 |
Total segment revenue | 50,493 |  |  | 44,841 |
Corporate (1) | (6) |  |  | (5) |
Total revenue | $ | 50,487 |  |  | $ | 44,836 |
| Nine Months Ended March 31,
(in millions) | 2023 |  | 2022
United States | $ | 148,136 |  |  | $ | 130,933 |
International | 3,433 |  |  | 3,339 |
Total segment revenue | 151,569 |  |  | 134,272 |
Corporate (1) | (10) |  |  | (11) |
Total revenue | $ | 151,559 |  |  | $ | 134,261 |
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment | The following tables present segment profit by reportable segment and Corporate:
| Three Months Ended March 31,
(in millions) | 2023 |  | 2022
Pharmaceutical (1) | $ | 600 |  |  | $ | 487 |
Medical | 20 |  |  | 59 |
Total segment profit | 620 |  |  | 546 |
Corporate | (48) |  |  | (643) |
Total operating earnings/(loss) | $ | 572 |  |  | $ | (97) |
| Nine Months Ended March 31,
(in millions) | 2023 |  | 2022
Pharmaceutical (1) | $ | 1,495 |  |  | $ | 1,319 |
Medical | 29 |  |  | 232 |
Total segment profit | 1,524 |  |  | 1,551 |
Corporate | (934) |  |  | (2,183) |
Total operating earnings/(loss) | $ | 590 |  |  | $ | (632) |
(1)Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18 million incurred during the three and nine months ended March 31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during the nine months ended March 31, 2022 was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.
Assets by Reportable Segment | The following table presents total assets for each reportable segment and Corporate at:
(in millions) | March 31, 2023 |  | June 30, 2022
Pharmaceutical | $ | 27,954 |  |  | $ | 26,409 |
Medical (1) | 10,544 |  |  | 11,632 |
Corporate | 4,879 |  |  | 5,837 |
Total assets | $ | 43,377 |  |  | $ | 43,878 |
(1)Medical reflects cumulative $863 million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the nine months ended March 31, 2023.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph a -SubTopic 10 -Topic 280 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration